Apyx Medical Corporation (APYX) Stock

Understand Apyx Medical Corporation: how it makes money

Apyx Medical Corporation develops and sells medical devices used in cosmetic and surgical procedures, including its Helium Plasma Generator technology and its Renuvion branded products, and it also performs Original Equipment Manufacturing (OEM) for device partners.

The profit model is closely tied to the Renuvion platform installed base, because sales are reported to come primarily from existing Renuvion platform customers rather than new customers.

Business quality (Weak): The latest-quarter financials show high gross margin (63.5%) but a negative operating margin (-7.3%), while the provided operating indicators emphasize Renuvion procedure activity and the mix of sales from existing versus new platform customers. Reported revenue and segment revenue figures appear very small and may be impacted by rounding (revenue_b is shown as 0.0B).

Bull case

• Platform-led demand signal: Operating indicators show large procedure activity (Renuvion Procedures Performed = 400000) and a meaningful installed base (Units Globally = 90000), which supports visibility into usage of the Renuvion technology.
• Sales skew toward existing platform customers: Aon Sales From Existing Renuvion Platform Customers is reported at 80%, versus Aon Sales From New Customers at 20%, indicating the business is generating a majority of sales from the existing Renuvion platform customer base.
• Strong gross margin in the quarter: For the period ended 2026-03-31, gross_margin_pct is 63.5%, which suggests products and mix can generate substantial gross profit even though operating costs remain a challenge.

Bear case

• Operating losses despite strong gross margin: Operating_margin_pct is -7.3% for the period ended 2026-03-31, so operating expenses are exceeding gross profit in the latest quarter.
• Small reported revenue base (rounding risk): Revenue_b is shown as 0.0B and segment revenues are very small (0.01B each for Surgical Aesthetics and Advanced Energy). This makes trend interpretation sensitive to rounding and may limit comparability.
• Dependence on procedure adoption and platform expansion: Because operating metrics highlight Renuvion procedures performed and platform customer sales mix, weaker adoption, fewer procedures, or slower platform growth could pressure results. (The company’s success depends on physicians and procedures using its technology.)

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Pro-Dex, Inc. (PDEX)
• Lucid Diagnostics Inc. (LUCD)
• Femasys Inc. (FEMY)
• KORU Medical Systems, Inc. (KRMD)
• Microbot Medical Inc. (MBOT)
• Pulmonx Corporation (LUNG)
• Sharps Technology, Inc. (STSS)
• CVRx, Inc. (CVRX)